Skip to main content
    H

    Harvard Bioscience Inc (HBIO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $8.91
    -0.48 (-5.11%)

    Market Cap: $42.94M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Harvard Bioscience Inc (HBIO) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Harvard Bioscience (HBIO) trades at 0.5x sales and 8.0x book value. Its forward P/E is 15.1x.

    Current Multiples

    Its enterprise value is 117.4x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E15.1x
    Price to sales0.5x
    Price to book8.0x
    EV/EBITDA117.4x
    PEGN/A
    FCF yield-7.8%
    As of Nov 17, 2026

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 21.6x in 2018 to 48.8x in 2020.

    Year endPriceP/EP/SP/B
    2025$6.69N/AN/A2.2x
    2024$21.10N/A0.4x0.1x
    2023$53.5046.9xN/AN/A
    2022$27.7033.0xN/A16.0x
    2021$70.5039.6xN/AN/A
    2020$42.9048.8x2.6x21.7x
    2019$30.5028.2xN/A1.4x
    2018$31.8021.6xN/AN/A
    2017$33.0038.8xN/AN/A
    2016$30.5026.8xN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HBIO

    What is HBIO's forward P/E ratio?

    Harvard Bioscience has a forward P/E ratio of 15.1x.

    Is HBIO stock overvalued?

    GNG's valuation label for HBIO is Overvalued.

    What is HBIO's price to sales ratio?

    Harvard Bioscience has a price to sales ratio of 0.5x.